ArticleFrontiers in oncology2020
Recurrence/Regrowth in Grade I Meningioma: How to Predict?
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Clinico-Histomorphological and Mib-1 Analysis of Recurrent Meningiomas: A Retrospective Study.Asian journal of neurosurgery · 2025Article
- SUV-max ofJournal of neuro-oncology · 2025Article
- Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.Cureus · 2025Article
- Article
- A nomogram to predict cancer-specific mortality in adult patients with malignant meningioma: a competing risk analysis.Discover oncology · 2024Article
- A comprehensive correlation of the KI-67 proliferation index to patient´s, imaging and tumor features and its value in predicting long-term course of patients with newly diagnosed intracranial meningiomas.Neurosurgical review · 2024Article
- Review
- Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma.Journal of neurosurgery · 2023Article
- Preoperative prediction of Ki-67 and p53 status in meningioma using a multiparametric MRI-based clinical-radiomic model.Frontiers in oncology · 2023Article
- Evaluation of P57, P53 and Ki67 Expression in Meningiomas.Journal of Korean Neurosurgical Society · 2022Article
- HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.International journal of molecular sciences · 2022Review
- Bilateral Meningioma: A Case Report and Review of the Literature.International journal of molecular sciences · 2022Review
- Expression of Progesterone Receptor and Its Association with Clinicopathological Characteristics in Meningiomas: A Cross-Sectional Study.World neurosurgery: X · 2021Article
- Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications.Frontiers in oncology · 2021Article
- P53 Suppressor Gene Tissue Microarray-based Protein Expression Analysis in Meningiomas.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.